Johnson & Johnson (JNJ)vsSo-Young International Inc (SY)
JNJ
Johnson & Johnson
$254.66
+3.99%
HEALTHCARE · Cap: $613.02B
SY
So-Young International Inc
$1.32
-4.93%
HEALTHCARE · Cap: $157.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 5709% more annual revenue ($96.36B vs $1.66B). JNJ leads profitability with a 21.8% profit margin vs -15.6%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SY
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.1%
Fair Value
$136.12
Current Price
$254.66
$118.54 premium
Intrinsic value data unavailable for SY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Revenue surging 45.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
ROE of -17.2% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SY
The strongest argument for SY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.6% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SY
The primary concerns for SY are Market Cap, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SY is a hypergrowth play — different risk/reward profiles.
SY carries more volatility with a beta of 1.98 — expect wider price swings.
SY is growing revenue faster at 45.6% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 44/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →So-Young International Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · China
So-Young International Inc. operates an online platform for consumer health and medical aesthetic services that focuses on discretionary medical treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?